Concurrent Session

Concurrent Group II



The concurrent sessions cover topics from across the spectrum of stem cell research. Each session, framed by a brief topic overview, includes one or two invited speakers whose work highlights leading research in the field. The session is rounded out with four or more abstract-selected speakers who, combined with the invited talks, give an excellent snapshot of the most current work on the topic. The five concurrent sessions run in parallel and attendees are encouraged to move between sessions to hear talks of interest. Concurrent sessions are held Thursday, Friday, and Saturday afternoons.

Concurrent IIC: Road to the Clinic 1

6/21/2018
16:00 - 18:00

Presentations:

Roger Barker

University of Cambridge

Roger Barker is the Professor of Clinical Neuroscience at the University of Cambridge and Consultant Neurologist at the Addenbrooke's Hospital Cambridge. He is a guest professor at the University of Lund, Sweden and a PI in the MRC-Wellcome Trust Stem Cell Institute in Cambridge. For the last 25 years he has run research that seeks to better define the clinical heterogeneity of two common neurodegenerative disorders of the CNS- namely Parkinson's (PD) and Huntington's disease (HD). This has helped him define the best way by which to take new treatments into the clinic, in particular cell based therapies. He currently co-ordinates an EU funded transplant programme using human fetal tissue for patients with PD and is part of a new EU and global initiative (GFORCE-PD) that is seeking to take stem cells to trial in patients with PD.

Presentation(s):

Send Email for Roger Barker

Xiuyan Wang

Memorial Sloan Kettering Cancer Center, United States

Dr. Wang is the Assistant Director of the Cell Therapy and Cell Engineering Facility at Memorial Sloan Kettering Cancer Center. She has overseen the successful manufacturing of over 300 clinical cell products including lymphocytes and stem cells for phase I/II clinical trials, as well as viral vectors. Dr. Wang is actively participating in the National Institute for Innovation in Manufacturing Biopharmaceuticals. She is also a member for the Translational Science and Product Development Committee for ASGCT.

Presentation(s):

Send Email for Xiuyan Wang

Charles E. Murry

University of Washington, WA, United States

Dr. Charles (Chuck) Murry received his MD-PhD at Duke University, studying myocardial ischemia-reperfusion injury. He did residency training in Pathology at the University of Washington, followed by fellowships in vascular biology and diagnostic cardiovascular pathology. He is currently a professor of Pathology, Bioengineering, and Medicine/Cardiology at the UW. Dr. Murry’s research focuses on stem cell biology, emphasizing differentiation of the human cardiovascular system and using these cells to study diseases and to regenerate damaged tissues. His group is a world leader in heart regeneration and is working toward a clinical trial using cardiomyocyte therapy. Murry is Director of the UW Institute for Stem Cell and Regenerative Medicine, Director of the UW Medicine Heart Regeneration Program, and Co-Director of the UW Center for Cardiovascular Biology.

Presentation(s):

Send Email for Charles Murry

Send Email for John Hallett

Send Email for Isabelle de Luzy

Roger Barker

University of Cambridge

Roger Barker is the Professor of Clinical Neuroscience at the University of Cambridge and Consultant Neurologist at the Addenbrooke's Hospital Cambridge. He is a guest professor at the University of Lund, Sweden and a PI in the MRC-Wellcome Trust Stem Cell Institute in Cambridge. For the last 25 years he has run research that seeks to better define the clinical heterogeneity of two common neurodegenerative disorders of the CNS- namely Parkinson's (PD) and Huntington's disease (HD). This has helped him define the best way by which to take new treatments into the clinic, in particular cell based therapies. He currently co-ordinates an EU funded transplant programme using human fetal tissue for patients with PD and is part of a new EU and global initiative (GFORCE-PD) that is seeking to take stem cells to trial in patients with PD.

Presentation(s):

Send Email for Roger Barker

Silviu Itescu

Mesoblast LTD, Australia

Mesoblast founder Dr Silviu Itescu has established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. He’s been a faculty member of Columbia University in New York and the University of Melbourne and Monash University in Australia. In 2013, he received the inaugural Key Innovator Award from the Vatican’s Pontifical Council for Culture for his leadership in cell-based translational science and clinical medicine.

Presentation(s):

Send Email for Silviu Itescu


Assets

Concurrent IIC: Road to the Clinic 1



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Concurrent IIC: Road to the Clinic 1